Glenview Trust co lessened its holdings in Waters Co. (NYSE:WAT – Free Report) by 13.0% during the fourth quarter, HoldingsChannel reports. The firm owned 7,337 shares of the medical instruments supplier’s stock after selling 1,100 shares during the quarter. Glenview Trust co’s holdings in Waters were worth $2,722,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Advisory Alpha LLC boosted its stake in Waters by 2.6% in the fourth quarter. Advisory Alpha LLC now owns 1,065 shares of the medical instruments supplier’s stock valued at $395,000 after buying an additional 27 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in shares of Waters by 2.4% in the 3rd quarter. Summit Trail Advisors LLC now owns 1,198 shares of the medical instruments supplier’s stock valued at $431,000 after purchasing an additional 28 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Waters by 3.0% during the 4th quarter. Empowered Funds LLC now owns 966 shares of the medical instruments supplier’s stock valued at $358,000 after purchasing an additional 28 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. lifted its stake in Waters by 0.3% in the 4th quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 9,610 shares of the medical instruments supplier’s stock valued at $3,565,000 after purchasing an additional 30 shares during the last quarter. Finally, OneDigital Investment Advisors LLC boosted its position in Waters by 3.8% in the third quarter. OneDigital Investment Advisors LLC now owns 851 shares of the medical instruments supplier’s stock valued at $306,000 after buying an additional 31 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. UBS Group upped their price target on shares of Waters from $405.00 to $410.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Sanford C. Bernstein raised Waters from a “market perform” rating to an “outperform” rating and set a $430.00 target price for the company in a report on Friday, January 10th. Barclays raised Waters from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $360.00 to $415.00 in a research note on Monday, February 10th. JPMorgan Chase & Co. raised their price objective on shares of Waters from $380.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, March 6th. Finally, Scotiabank raised shares of Waters from a “sector perform” rating to a “sector outperform” rating and boosted their target price for the stock from $430.00 to $450.00 in a report on Thursday, February 13th. Eleven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Waters has a consensus rating of “Hold” and a consensus target price of $391.07.
Waters Stock Up 3.8 %
Shares of Waters stock opened at $378.18 on Monday. The firm has a market cap of $22.47 billion, a price-to-earnings ratio of 35.31, a PEG ratio of 3.79 and a beta of 1.00. The stock’s 50-day moving average is $391.24 and its 200 day moving average is $370.48. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.94 and a quick ratio of 0.65. Waters Co. has a one year low of $279.24 and a one year high of $423.56.
Waters (NYSE:WAT – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. Equities research analysts anticipate that Waters Co. will post 12.86 EPS for the current year.
Waters Profile
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
See Also
- Five stocks we like better than Waters
- Stock Splits, Do They Really Impact Investors?
- How to Build the Ultimate Everything ETF Portfolio
- Stock Sentiment Analysis: How it Works
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Consumer Staples Stocks, Explained
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT – Free Report).
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.